IFP Advisors’s Verrica Pharmaceuticals VRCA Stock Holding History

IFP Advisors’s Portfolio VRCA Stock Details VRCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1	Closed	-$3	–	4950
2025 Q2	$3	Buy	+1	New	+$5	﹤0.01%	4896

Other funds holding VRCA

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sovran Advisors San Diego, California $1.27B AUM 18.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

IFP Advisors's VRCA Position: Q3 2025 in Review

IFP Advisors sold out of Verrica Pharmaceuticals (VRCA) in Q3 2025, closing a stake of 1 share — an estimated $3 sold.

IFP Advisors first reported a position in VRCA in Q2 2025 and held it in 1 quarter. The position peaked at $3 in Q2 2025. 34 funds tracked by Wall St. Rank hold VRCA as of Q3 2025.

IFP Advisors reported no remaining Verrica Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
IFP Advisors sold 1 Verrica Pharmaceuticals share in Q3 2025, an estimated $3.
IFP Advisors first reported a position in Verrica Pharmaceuticals in Q2 2025 and held it in 1 quarter.
IFP Advisors's Verrica Pharmaceuticals position peaked at $3 in Q2 2025.
34 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2025.

Based on IFP Advisors's 13F filing for Q3 2025, filed 2 Dec 2025.